Exemestane in Advanced and Recurrent Endometrial Carcinoma

Phase 2 Study of Exemestane in Advanced and Recurrent Endometrial Carcinoma

A phase II study of Exemestane in Advanced or recurrent endometrial carcinoma

Hypothesis: Treatment With Exemestane can give a response rate of at least 30%

Patients With Advanced or recurrent endometrial cancer of endometrioid type were treated With Exemestane tablets 25 mg daily.

Patients were grouped according to estrogen receptor status.

Inclusion Criteria:

• Advanced or recurrent endometrial cancer not considered for treatment modalities apart from hormonal treatment
• Endometrioid histology
• Age above 18 years
• Post menopausal status
• Performance status 0-2
• Informed consent

Exclusion Criteria:

• Congestive heart disease grade III.IV
• History of thromboembolic signs
• Other primary hormonal therapy
• Patients With symptomatic brain metastasis
• Severe hepatic or renal impairment
• Pregnancy, lactation or child bearing potential without adequate contraception